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Abstract
HumanT-cell leukemia virus type I (HTLV-I) is the etiological agent of adult T-cell leukemia (ATL).Our recent studieshave
shown that one important mechanism of HTLV-I–mediated tumorigenesis is through PDZ-LIM domain-containing
protein 2 (PDLIM2) repression, although the involved mechanism remains unknown. Here, we further report that
HTLV-I–mediated PDLIM2 repression was a pathophysiological event and the PDLIM2 repression involved DNAmeth-
ylation. Whereas DNA methyltransferases 1 and 3b but not 3a were upregulated in HTLV-I–transformed T cells, the
hypomethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) restored PDLIM2 expression and induced death of these
malignant cells. Notably, the PDLIM2 repression was independent of the viral regulatory protein Tax because neither
short-term induction nor long-term stable expression of Tax could downregulate PDLIM2 expression. These studies
provide important insights into PDLIM2 regulation, HTLV-I leukemogenicity, long latency, and cancer health disparities.
Given the efficient antitumor activity with no obvious toxicity of 5-aza-dC, these studies also suggest potential thera-
peutic strategies for ATL.
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Introduction
Human T-cell leukemia virus type I (HTLV-I) infection causes an ag-
gressive and fatal CD4+ T-cell malignancy termed adult T-cell leukemia
(ATL) in approximately 2% to 5% virus carriers after an extensive
latency period. Although the detailed mechanisms of ATL development
remain ill defined, it seems clear that the early stage of HTLV-I–
mediated leukemogenesis is largely mediated by its encoded regulatory
protein Tax [1,2]. Tax is able to transform many different types of cells
in vitro and induce tumors in mice. Conversely, the HTLV-I genome
without Tax loses its original oncogenic ability.
The Tax oncoprotein exerts its transforming action largely through
deregulation of cellular transcription factors that are critical for cell
growth and division, such as nuclear factor κB (NF-κB) [1,2]. The
mechanisms by which Tax deregulates the NF-κB signaling for tumori-
genesis have been well studied. In the cytoplasm, Tax recruits the inhibi-
tor of NF-κB (IκB) kinase (IKK) complex into specific compartments
for IKK activation [3,4], resulting in degradation of IκB and subsequent
nuclear translocation of NF-κB factors including p65, also known as
RelA, the prototypic member of NF-κB [5]. In the nucleus, Tax recruits
p65 and other cellular transcriptional components into interchromatin
granules to form discrete transcriptional hot spots termed as Tax nuclear
bodies for full NF-κB transcriptional activation [6,7].
Contrast to the mechanisms by which Tax hijacks cellular signaling
to initiate malignant transformation leading to the development of
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ATL, the molecular studies on howHTLV-I/Tax is regulated by cellular
factors are still lacking. Recently, we have identified the PDZ-LIM
domain-containing protein 2 (PDLIM2) as a potent suppressor of
Tax [8]. PDLIM2 not only promotes Tax polyubiquitination but also
binds to and shuttles Tax from its functional sites including the peri-
nuclear structures and Tax nuclear foci into the nuclear matrix for pro-
teasomal degradation. Accordingly, PDLIM2 prevents downstream
signaling and subsequent tumorigenicity of HTLV-I/Tax. Interestingly,
PDLIM2 is conversely repressed in various HTLV-I–transformed cells
at the RNA level. These studies clearly suggest that PDLIM2 repression
is one important mechanism of HTLV-I–mediated tumorigenesis.
However, whether the PDLIM2 repression occurs under pathophysio-
logical conditions and how HTLV-I represses PDLIM2 expression still
remain unknown.
Here, we further report that HTLV-I repressed PDLIM2 expression
in primary ATL cells freshly isolated from patients and established ATL
cell line. However, the PDLIM2 repression was independent of the viral
oncoprotein Tax because neither short-term induction nor long-term
stable expression of Tax could downregulate PDLIM2 expression.
Instead, the HTLV-I–mediated PDLIM2 repression involved DNA
methylation. Whereas DNA methyltransferases 1 (DNMT1) and 3a
(DNMT3b) but not 3a (DNMT3a) were upregulated in HTLV-I–
transformed T cells, the hypomethylating agent 5-aza-2′-deoxycytidine
(5-aza-dC) restored PDLIM2 expression. Interestingly, we also find that
in association with the reactivation of PDLIM2, 5-aza-dC was able to
induce death of HTLV-I–transformed T cells in a dose-dependent
manner. These studies not only provide important insights into
PDLIM2 regulation and HTLV-I leukemogenicity but also suggest po-
tential therapeutic strategies for ATL.
Materials and Methods
Reagents
Tax antibody was generated as described [9]. Fetal bovine serum
(FBS), doxycycline, and 5-aza-dC were from Hyclone Laboratories
(Logan, UT) and Sigma (St. Louis, MO), respectively.
Cell Culture
Jurkat andHTLV-I–transformed cell linesweremaintained in suspen-
sion in RPMI 1640 medium supplemented with 10% FBS and 2 mM
L-glutamine [10,11]. Mouse embryonic fibroblasts (MEFs) were cul-
tured in Dulbecco’s modified Eagle medium supplemented with 10%
FBS and 2 mM L-glutamine [12–14].
Induction of Tax in Jurkat-Inducible Cell Line
For Tax induction, Jurkat-TetOn–inducible cells maintained in 10%
tetracycline-free FBS were treated with 0.1 μg/ml doxycycline for the
indicated time as described before [15]. The cells were then lysed in
RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mMNaCl, 1 mM EDTA,
0.25% (wt/vol) Na-deoxycholate, 1% (vol/vol) NP-40, 1 mM DTT)
for whole lysate extraction (for immunoblot analysis) or in TRIzol
reagent (Invitrogen, Carlsbad, CA) for RNA extraction (for reverse
transcription–polymerase chain reaction [RT-PCR]).
Clinical Samples
With informed consent according to the Helsinki Declaration,
peripheral blood mononuclear cells (PBMCs) were obtained from five
patients with acute-type ATL (nos. 1-5) and two healthy volunteers
(nos. 1 and 2). The diagnosis of ATL was established hematologically,
andmonoclonal HTLV-Iprovirus integration into the genome was con-
firmed by Southern blot hybridization in all cases (data not shown). Sub-
types of ATL were defined as described before [16,17]. Mononuclear
cells were isolated from heparinized venous blood samples by Ficoll
Paque gradient centrifugation (GE Healthcare Biosciences, Uppsala,
Sweden). Each patient sample contained more than 90% leukemic cells
at the time of analysis. All samples were collected at the time of ad-
mission to hospital before the patients started chemotherapy. The nor-
mal PBMC control nos. 3 and 4 were purchased from the Biologic
Specialty Corporation (Colmar, PA).
RT-PCR Analysis
Total RNA was prepared with TRIzol reagent, and complementary
DNAwas generatedwith SuperScript II reverse transcriptase (Invitrogen),
Figure 1. HTLV-I represses PDLIM2 expression in primary ATL cells. The relative levels of PDLIM2 mRNA in PBMCs directly from ATL
patients or established ATL cell line TL-Om1 were analyzed by real-time PCR and normalized according to GAPDH mRNA level and
represented as percentile in cells from healthy control no. 1 (arbitrarily set as 100). Data presented are the mean ± SD (n = 3).
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followed by normal RT-PCR or real-time RT-PCR as described we
before [18,19]. Primer pairs for RT-PCR were as follows: mouse
PDLIM2, forward 5′-GACAGCCAGTCTTCCCAGAG and reverse
5′-TCTCACAGGTGTGGAGCTTG; Tax, forward 5′-CACCTGT-
CCAGAGCATCAGAand reverse 5′-CGCTTGTAGGGAACATTGGT;
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward 5′-
CACAGTCCATGCCATCACTG and reverse 5′-CTTACTCCTT-
GGAGGCCATG. Primer pairs for real-time PCR were as follows:
human PDLIM2, forward 5′-GCCCATCATGGTGACTAAGG and
reverse 5′-ATGGCCACGATTATGTCTCC; human β-actin, forward
5′-ATCAAGATCATTGCTCCTCCT and reverse 5′-GAGAGCGA-
GGCCAGGATGGA; humanGAPDH, forward 5′-GCAAATTCCAT-
GGCACCGTand reverse 5′-TCGCCCCACTTGATTTTGG; human
DNMT1, forward 5′-GGTTCTTCCTCCTGGAGAATGTC and
reverse 5′-GGGCCACGCCGTACTG; human DNMT3a, forward
5′-GCCTCAATGTTACCCTGGAA and reverse 5′-CAGCAGATGG-
TGCAGTAGGA; human DNMT3b, forward 5′-CCCATTCGAG-
TCCTGTCATTand reverse 5′-GGTTCCAACAGCAATGGACT.
Results
PDLIM2 Is Repressed in Primary ATL Cells
Our recent studies showed that PDLIM2 is repressed at the RNA
level in various T-cell lines in vitro transformed by HTLV-I [8]. To fur-
ther substantiate the findings, we examined messenger RNA (mRNA)
levels of PDLIM2 in primary ATL cells. Indeed, the expression levels of
PDLIM2 were much lower in primary ATL cells directly from patients
or established ATL cell line TL-Om1 compared with that in healthy
control cells (Figure 1). These results indicated that PDLIM2 down-
regulation is an HTLV-I pathophysiological event, further supporting
our original finding that PDLIM2 repression is one important mecha-
nism of HTLV-I–mediated tumorigenesis [8].
Figure 2. HTLV-I represses RNA expression of PDLIM2 independent
of Tax. (A) Tax-inducible Jurkat cells were mock-treated or treated
with doxycycline for the indicated times followed by real-time
PCR. The induction of Tax protein was analyzed by direct immuno-
blot analysis. (B) MEF cells stably expressing Tax or an empty vector
were used for RT-PCR to check expressions of the indicated genes.
Figure 3. HTLV-I–mediated repression of PDLIM2 involves DNA
methylation. (A) The indicated cells were treated with the hypo-
methylating agent 5-aza-dC for 48 hours followed by real-time PCR.
PDLIM2 mRNA were normalized according to β-actin mRNA level
and represented as fold induction in mRNA abundance relative to
that in the mock-treated sample of each request. Data presented
are the mean ± SD (n = 3). (B) RNA expression levels of DNMT1,
DNMT3a, and DNMT3b were analyzed in the indicated cell lines by
real-timePCR.RNA levels of individualDNMTs inHTLV-I–transformed
T cells were normalized according to β-actin mRNA level and rep-
resented as fold induction in mRNA abundance relative to that in
normal PBMCs (set as 1). Data presented are the mean ± SD (n =
3). (C) Tax-inducible Jurkat cells were mock-treated or treated with
doxycycline for 36 hours followed by real-time PCR to check the
relative RNA expression levels of DNMT1, DNMT3a, and DNMT3b.
RNA levels of individual DNMTs in doxycycline-treated (Dox) cells
were normalized according to β-actin mRNA level and represented
as percentile of that in the mock-treated (NT) cells (set as 100). Data
presented are the mean ± SD (n = 3).
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PDLIM2 Repression by HTLV-I Is Independent of Tax
Currently, the mechanism of PDLIM2 regulation, including that by
which PDLIM2 expression is repressed by HTLV-I, still remains un-
known. To address this important issue, we initially tested whether
the Tax oncoprotein is involved, giving its role in gene regulation and
cellular transformation. Consistent with our previous studies showing
that Jurkat cells, an HTLV-I–negative leukemic T-cell line, express
abundant PDLIM2 [8], we found a high expression of PDLIM2 in
Tax-inducible Jurkat cells in the absence of Tax expression (Figure 2A).
However, Tax induction had no obvious effect on PDLIM2 expression.
It should be noted that Jurkat cells would die 72 to 96 hours after
Tax induction because of Tax-induced TRAIL and, subsequently,
TRAIL-mediated apoptosis [20]. To rule out that the failure of the
PDLIM2 repression was not due to short period of Tax expression,
we compared the PDLIM2 expression levels inMEF cells stably expres-
sing Tax or an empty vector. It was noteworthy that the Tax MEF cells
have acquired the ability to form foci in soft agar and tumor in mice [8].
As shown in Figure 2B, a long period of Tax expression in these trans-
formed cells also failed to downregulate PDLIM2 expression. Thus, it
seemed that HTLV-I represses PDLIM2 expression independent of
Tax. In agreement with this, PDLIM2 expression is also repressed
in primary ATL cells and ATL cell line TL-Om1 (Figure 1), which
already lost Tax expression [10,17].
PDLIM2 Repression by HTLV-I Involves DNA Methylation
We then examined the potential role ofDNAmethylation, onemajor
mechanism responsible for the repression of tumor suppressor genes in
neoplastic cells [21]. Interestingly, treatment of the hypomethylating
agent 5-aza-dC significantly increased RNA expression of PDLIM2 in
T-cell lines either in vitro transformed by HTLV-I or established from
ATL patients (Figure 3A). Conversely, the treatment of 5-aza-dC led to a
slight decrease of PDLIM2 in Jurkat cells. These results suggested that
DNAmethylation contributes specifically to HTLV-I–mediated repres-
sion of PDLIM2.
The methylation of mammalian genomic DNA is mediated by
three DNA methyltransferases, namely, DNMT1, DNMT3a, and
DNMT3b [21]. Nucleoside analog 5-aza-dC inhibits all three en-
zymes. To identify the methyltransferase(s) involved in HTLV-I–
mediated PDLIM2 repression, we examined their expression levels in
various HTLV-I–transformed T-cell lines including C8166, MT-4,
SLB-1, Hut102, and TL-Om1. As shown in Figure 3B, DNMT1 and
DNMT3b were upregulated significantly and consistently in all
these HTLV-I–transformed T-cell lines, although to different extents.
Conversely, DNMT3a was only slightly upregulated in certain cell
lines but decreased in others. Thus, it seemed that DNMT1 and
DNMT3b but not DNMT3a may be involved in HTLV-I–mediated
repression of PDLIM2. In support of this, it is well known that
DNMT1 and DNMT3b but not DNMT3a usually cooperate to in-
activate tumor suppressor genes in cancer cells but not in nonmalig-
nant cells [21].
These results also implied that the up-regulation of DNMT1 and
DNMT3b in HTLV-I–transformed T cells is independent of Tax
expression because whereas C8166, MT-4, SLB-1, and Hut102 cells
still express Tax, the ATL cell line TL-Om1 already loses Tax ex-
pression [8,10,17]. To further confirm this, we examined whether
Tax induction affects the expression of different DNMTs in Jurkat
cells. As shown in Figure 3C , Tax induction had no obvious ef-
fect on the expression of all three DNMTs. Taken together, these
results suggested that Tax is not involved in the up-regulation of
DNMT1 and DNMT3b in HTLV-I–transformed T cells. These
studies further supported that PDLIM2 repression by HTLV-I is inde-
pendent of Tax.
Treatment of 5-aza-dC Leads to Death of HTLV-I–
Transformed T Cells
In association with reactivation of PDLIM2, interestingly, the treat-
ment of 5-aza-dC resulted in death of HTLV-I–transformed T cells in a
dose-dependent manner (Figure 4). Although 5-aza-dC is unable to fur-
ther increase PDLIM2 expression in Jurkat cells, it could also induce
death of the leukemic cells in a dose-dependent manner. Conversely,
normal PBMCs were largely resistant to 5-aza-dC–induced death.
These results suggested that 5-aza-dC–induced cancer cell death may
involve different target genes. Nevertheless, these results were consistent
with the fact that 5-aza-dC is toxic to cancer cells but not normal cells
[21,22]. Currently, there is no beneficial treatment for ATL patient
except the bone marrow transplantation because of the high resistance
of ATL cells to cancer therapy–induced death [23]. These results thus
suggested an immediate therapeutic approach for the poorly diagnos-
Figure 4. Hypomethylating agent 5-aza-dC induces apoptosis of HTLV-I–transformed T cells in a dose-dependent manner. The indicated
cells were treated with increasing doses of 5-aza-dC for 72 hours followed by Trypan blue counting of dead and viable cells. The presented
percentiles of viable cells were normalized to the percent viability of mock-treated cells (denoted as 100%). Data presented are the mean ±
SD (n = 3).
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tic disease ATL, although targets of 5-aza-dC other than PDLIM2 were
also involved.
Discussion
Under physiological conditions, PDLIM2 is expressed in most tissues,
with the highest expression in the lungs; modest in thymus, spleen,
kidney, and testis; and low in the brain, heart, and muscle [24–26]. At
the cellular level, PDLIM2 expression is high in various hematopoietic
cells including CD4+ T cells [26], the targets of HTLV-I. Data presented
in this study indicate that PDLIM2 expression was significantly down-
regulated in freshly isolated primary ATL cells and established ATL cell
line (Figure 1). Given the ability of PDLIM2 in suppressing tumorige-
nicity of HTLV-I–transformed T cells [8], this study suggests that
PDLIM2 repression is one pathophysiologically important mechanism
of HTLV-I–mediated ATL.
Our mechanistic studies further suggest that HTLV-I–mediated
PDLIM2 repression involves DNA methylation, which may be me-
diated specifically by DNMT1 and DNMT3b. We have shown that
the hypomethylating agent 5-aza-dC could significantly reinduce
expression of PDLIM2 in both HTLV-I–transformed T cells and
ATL cells (Figure 3). In addition, DNMT1 and DNMT3b, but not
DNMT3a, were upregulated significantly and consistently in these
malignant T cells (Figure 3). These findings are highly consistent with
the cooperative role of DNMT1 and DNMT3b but not DNMT3a in
the inactivation of tumor suppressor genes in cancer cells but not in
nonmalignant cells [21]. However, it should be noted that the expres-
sion levels of DNMTs are correlated generally but imperfectly with
the expression levels of PDLIM2 as well as the induction of PDLIM2
by 5-aza-dC in different HTLV-I–transformed T cells. One imme-
diate explanation is that epigenetic regulation is complex in cell and
gene contexts. The repression extent of a particular gene not only re-
quires availability of individual DNMTs but also depends on their
ratios and the availabilities of many other cellular factors. In this re-
gard, it is well known that in addition to cooperating with each other,
DNMTs associate with histone deacetylase 1, histone methyltransferase
SUV39H1, and methyl-CpG-binding proteins-domains for gene re-
pression [21].
In association with the reactivation of PDLIM2, 5-aza-dC could ef-
ficiently induce death of HTLV-I–transformed T cells and ATL cells.
Because there is no obvious toxicity of 5-aza-dC observed in phase 3
clinical trials for patients with myelodysplastic syndromes and acute
myelogenous leukemia [22], our studies therefore suggest an immediate
therapeutic approach for ATL. This is particularly interesting because
HTLV-I–transformed cells are highly resistant to the induction of
apoptosis and there is still no actually beneficial treatment other than
allogeneic hematopoietic stem cell transplantation for this acute and
fatal disease [23]. Clearly, the effect of 5-aza-dC could not attribute only
to the reactivation of PDLIM2. Other yet-identified targets of this anti-
tumor drug also play very important roles in the death of HTLV-I–
transformed T cells.
Although Tax plays a critical role in the initial phases of HTLV-I–
mediated leukemogenesis, there are several pieces of evidence suggest-
ing that HTLV-I represses PDLIM2 expression independent of the key
viral regulatory protein. First, PDLIM2 is repressed in Tax-negative
ATL cells in addition to Tax-positive HTLV-I–transformed T cells (Fig-
ure 1). Second, Tax is dispensable for the specific up-regulation of
DNMT1 and DNMT3b in HTLV-I–transformed T cells, although
DNA methylation plays an important role in the PDLIM2 repression
in these malignant cells (Figure 3). Most importantly, neither short-
term induction nor long-term stable expression of Tax could down-
regulate PDLIM2 expression (Figure 2).
In summary, our studies suggested that HTLV-I–mediated repression
of PDLIM2 occurs under pathophysiological conditions and that the
PDLIM2 repression involves DNA methylation possibly through
specific up-regulation of DNMT1 and DNMT3b. Our studies also ex-
cluded the role of Tax in the PDLIM2 repression. Given the death of
HTLV-I–transformed cells triggered by the antitumor drug 5-aza-dC,
these studies not only help understand regulation of PDLIM2, leuke-
mogenicity, long latency and cancer health disparities of HTLV-I but
also suggest a direct therapeutic strategy for ATL.
Acknowledgments
The authors thank M. Maeda and S. Yamaoka for MT-4 and TL-Om1
cells and W.C. Greene and E. Harhaj for TetOn Jurkat cells.
References
[1] Grassmann R, Aboud M, and Jeang KT (2005). Molecular mechanisms of cellular
transformation by HTLV-1 Tax. Oncogene 24, 5976–5985.
[2] Sun SC and Yamaoka S (2005). Activation of NF-κB by HTLV-I and implications
for cell transformation. Oncogene 24, 5952–5964.
[3] Harhaj NS, Sun SC, and Harhaj EW (2007). Activation of NF-κB by the human
T cell leukemia virus type I Tax oncoprotein is associated with ubiquitin-dependent
relocalization of IκB kinase. J Biol Chem 282, 4185–4192.
[4] Kfoury Y, Nasr R, Favre-Bonvin A, El-Sabban M, Renault N, Giron ML,
Setterblad N, Hajj HE, Chiari E, Mikati AG, et al. (2008). Ubiquitylated
Tax targets and binds the IKK signalosome at the centrosome. Oncogene 27,
1665–1676.
[5] Xiao G, Rabson A, Young W, Qing G, and Qu Z (2006). Alternative pathways of
NF-κB activation: a double-edged sword in health and disease. Cytokine Growth
Factor Rev 17, 281–293.
[6] Semmes OJ and Jeang KT (1996). Localization of human T-cell leukemia virus
type 1 Tax to subnuclear compartments that overlap with interchromatin speckles.
J Virol 70, 6347–6357.
[7] Bex F, McDowall A, Burny A, and Gaynor R (1997). The human T-cell leukemia
virus type 1 transactivator protein Tax colocalizes in unique nuclear structures with
NF-κB proteins. J Virol 71, 3484–3497.
[8] Yan P, Fu J, Qu Z, Li S, Tanaka T, Grusby MJ, and Xiao G (2009). PDLIM2
suppresses HTLV-I Tax-mediated tumorigenesis by targeting Tax into the nuclear
matrix for proteasomal degradation. Blood 113, 4370–4380.
[9] Qu Z, Qing G, Rabson R, and Xiao G (2004). Tax deregulation of NF-κB2 p100
processing involves both β-TrCP–dependent and independent mechanisms. J Biol
Chem 279, 44563–44572.
[10] Yan P, Qing G, Qu Z, Wu CC, Rabson A, and Xiao G (2007). Targeting auto-
phagic regulation of NF-κB in HTLV-I transformed cells by geldanamycin: impli-
cations for therapeutic interventions. Autophagy 3, 600–603.
[11] Qing G, Yan P, and Xiao G (2006). Hsp90 inhibition results in autophagy-
mediated proteasome-independent degradation of IκB kinase. Cell Res 16 (11),
895–901.
[12] Qing G and Xiao G (2005). Essential role of IκB kinase α in the constitutive pro-
cessing of NF-κB2 p100. J Biol Chem 280, 9765–9768.
[13] Qing G, Yan P, Qu Z, Liu H, and Xiao G (2007). Hsp90 regulates processing of
NF-κB2 p100 involving protection of NIK from autophagy-mediated degradation.
Cell Res 17 (6), 520–530.
[14] Vatsyayan J, Qing G, Xiao G, and Hu J (2008). SUMO-1 modification of
NF-κB2/p100 is essential for stimuli-induced p100 phosphorylation and pro-
cessing. EMBO Rep 9 (9), 885–890.
[15] KwonH,Ogle L, Benitez B, Bohuslav J,MontanoM, FelsherDW, andGreeneWC
(2005). Lethal cutaneous disease in transgenic mice conditionally expressing type I
human T cell leukemia virus Tax. J Biol Chem 280, 35713–35722.
[16] Shimoyama M (1991). Diagnostic criteria and classification of clinical subtypes
of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group
(1984–87). Br J Haematol 79, 428–437.
[17] Tomita M, Semenza GL, Michiels C, Matsuda T, Uchihara JN, Okudaira T,
Tanaka Y, TairaN,Ohshiro K, andMori N (2007). Activation of hypoxia-inducible
1040 PDLIM2 Repression by HTLV-I Yan et al. Neoplasia Vol. 11, No. 10, 2009
factor 1 in humanT-cell leukaemia virus type 1–infected cell lines and primary adult
T-cell leukaemia cells. Biochem J 406, 317–323.
[18] Qing G, Qu Z, and Xiao G (2007). Proteasome-mediated endoproteolytic process-
ing of the NF-κB2 precursor at the κB promoter. Proc Natl Acad Sci USA 104,
5324–5329.
[19] Qing G, Qu Z, and Xiao G (2005). Stabilization of basally translated NF-κB–
inducing kinase (NIK) protein functions as a molecular switch of processing of
NF-κB2 p100. J Biol Chem 280, 40578–40582.
[20] Rivera-Walsh I, Waterfield M, Xiao G, Fong A, and Sun SC (2001). NF-κB sig-
naling pathway governs TRAIL gene expression and human T-cell leukemia virus-I
Tax-induced T-cell death. J Biol Chem 276, 40385–40388.
[21] Luczak M and Jagodzinski PP (2006). The role of DNA methylation in cancer
development. Folia Histochem Cytobiol 44, 143–154.
[22] Garcia-Manero G (2008). Demethylating agents in myeloid malignancies. Curr
Opin Oncol 20, 705–710.
[23] MatsuokaMand JeangKT (2007).HumanT-cell leukaemia virus type 1 (HTLV-1)
infectivity and cellular transformation. Nat Rev Cancer 7, 270–280.
[24] Torrado M, Senatorov VV, Trivedi R, Fariss RN, and Tomarev SI (2004). Pdlim2,
a novel PDZ-LIM domain protein, interacts with α-actinins and filamin A. Invest
Ophthalmol Vis Sci 45, 3955–3963.
[25] Loughran G, Healy NC, Kiely PA, Huigsloot M, Kedersha NL, and O’Connor R
(2005). Mystique is a new insulin-like growth factor-I–regulated PDZ-LIM
domain protein that promotes cell attachment and migration and suppresses
anchorage-independent growth. Mol Biol Cell 16, 1811–1822.
[26] Tanaka T, Soriano MA, and Grusby MJ (2005). SLIM is a nuclear ubiquitin E3
ligase that negatively regulates STAT signaling. Immunity 22, 729–736.
Neoplasia Vol. 11, No. 10, 2009 PDLIM2 Repression by HTLV-I Yan et al. 1041
